Paris – 17 April 2014 – EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs[1],today celebrated the listing of Genfit in compartment B of Euronext’s regulated market in Paris.
Founded in 1999, with facilities in Lille (France) and Cambridge, Massachusetts (USA), Genfit is dedicated to developing therapeutic treatments and diagnostics in fields with major unmet needs, linked primarily to cardiometabolic disorders, with a particular focus on hepatitis complications including NASH[2]. To meet these major public health concerns, Genfit is developing a portfolio of drug candidates and biomarker candidates in its own R&D programs and in programs conducted jointly with large drug companies.
Genfit (ticker symbol: GNFT) was listed through the admission to trading of the 21,257,671 existing shares making up the company’s equity under the direct listing procedure on Euronext’s regulated market in Paris.
Market capitalisation stood at around €464.5 million on the day of listing.
“We are delighted to accompany Genfit as it enters this new stage in its growth,” said Eric Forest, Chairman and CEO of EnterNext, adding “Listing will raise the company’s profile with investors and give it access to greater liquidity to step up deployment of its strategy.”
Jean-François Mouney, Chairman of Genfit’s Management Board, added “Our transfer to compartment B of Euronext Paris is set to boost Genfit’s visibility as we are integrated into a range of benchmark indices, and will also appeal to investors who prefer Euronext’s regulated market.”